Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : I-mab crawled time : 12:15 save search
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
Published: 2021-07-30 (Crawled : 12:15) - prnewswire.com
IMAB | $1.8 39K
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
disease alzheimer treatment fda phase 1 approval phase 2 phase 3 alzheimer’s alzheimer's disease alzheimer's
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
Published: 2021-07-01 (Crawled : 12:15) - prnewswire.com
IMAB | $1.8 39K
|
Health Technology
|
| O: -2.28%
H: 3.41%
C: 2.91%
antibody
I-Mab Appoints Ruyi He and Rong Shao to Board of Directors
Published: 2021-06-01 (Crawled : 12:15) - prnewswire.com
IMAB | $1.8 39K
|
Health Technology
|
| O: 0.62%
H: 2.83%
C: -1.92%
I-Mab Announces Upcoming Participation at June Conferences
Published: 2021-05-27 (Crawled : 12:15) - prnewswire.com
IMAB | $1.8 39K
|
Health Technology
|
| O: 0.19%
H: 12.75%
C: 8.96%
conference
I-Mab Announces Upcoming Participation at May Conferences
Published: 2021-04-29 (Crawled : 12:15) - prnewswire.com
MS | News 0 d | $93.53 -0.25% 2.2M
|
Finance
|
| O: 0.57%
H: 0.71%
C: 0.53%
IMAB | $1.8 39K
|
Health Technology
|
| O: 0.93%
H: 1.32%
C: -0.91%
conference
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
Published: 2021-04-26 (Crawled : 12:15) - biospace.com/
IMAB | $1.8 39K
|
Health Technology
|
| O: 0.6%
H: 1.23%
C: 0.22%
phase 2 positive phase 2 results results topline ulcerative colitis
I-Mab Announces Upcoming Participation at April Conferences
Published: 2021-03-31 (Crawled : 12:15) - globenewswire.com
IMAB | $1.8 39K
|
Health Technology
|
| O: 0.13%
H: 3.73%
C: 2.63%
conference
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
Published: 2021-03-30 (Crawled : 12:15) - globenewswire.com
IMAB | $1.8 39K
|
Health Technology
|
| O: 3.45%
H: 4.76%
C: 2.74%
fda solid tumors phase 1 fda approval antibody trial approval phase 3 phase 2
I-Mab to Host 2021 R&D Day
Published: 2021-03-24 (Crawled : 12:15) - globenewswire.com
IMAB | $1.8 39K
|
Health Technology
|
| O: 1.45%
H: 2.78%
C: -8.03%
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.87 59.83% 100M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.